Keeping Track: US FDA Clears Sanofi’s Sarclisa; KemPharm Submits Novel ADHD Drug
Executive Summary
The latest drug development news and highlights from the Pink Sheet FDA Performance Tracker.
You may also be interested in...
Glaukos Gets Approval For Glaucoma Implant, With A Catch
Glaukos got US FDA approval for its intracameral implant of travoprost for glaucoma and hopes the product will work for up to three years. It also set a high goal for first-year sales.
FDA Sarclisa Approval Marks Sanofi's Reentry Into Oncology
The anti-CD38 antibody will face an entrenched rival, J&J's Darzalex, for multiple myeloma.
March Madness: Upcoming US FDA Decision Dates To Watch
A dozen applications for new drugs and significant new indications are on the US FDA’s calendar of goal dates, including breakthrough-designated applications from Bristol-Myers Squibb and Boehringer Ingelheim.